Eli Lilly (LLY) Stock Analysis: Can Its Obesity-Drug Lead Justify the Valuation?
Last reviewed: September 11, 2026 Eli Lilly and Company (NYSE: LLY) is no longer merely a diversified pharmaceutical manufacturer with a promising diabetes medicine. Mounjaro and Zepbound have become a global growth engine, Lilly is investing tens of billions of dollars in manufacturing, and its cardiometabolic pipeline could broaden the franchise from injections into oral … Read more